MENU
APR 14, 2021 9:00 AM PDT

Keynote Presentation: What the NIH Serosurvey Tells Us So Far and Why We Should Try to Develop a Broadly Protective/Universal Beta-Coronavirus Vaccine

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
    BIOGRAPHY

Abstract

Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population were selected by quota sampling from volunteers. Enrolled participants provided medical, geographic, demographic, socioeconomic information, and dried blood samples. The majority (88.7%) of samples were collected between May 10th and July 31st, 2020. The highest undiagnosed seropositivity was detected in Black/African American participants, younger, female, Hispanic, and Urban residents, and lower undiagnosed seropositivity in those with chronic diseases. These data indicate that there were 4.8 undiagnosed cases for every diagnosed case of COVID-19, and an estimated 16.8 million undiagnosed cases by mid-July 2020.  Given the high point estimate of undiagnosed seropositivity in younger donors, lower point estimates in individuals with pre-existing conditions such as diabetes, and the vaccine rollout starting with older persons and those at risk, long-term study of naturally acquired immunity, vaccine acquired immunity, and vaccine boosted naturally acquired immunity will be necessary to fully understand the correlates of protection, durability of SARS-CoV-2 immunity, and the impact immunity will have long-term on the spread of SARS-CoV-2 and other future variants or novel coronaviruses. It is also clear from these data that novel coronaviruses can spread rapidly throughout human populations despite public health measures and we must therefore prepare for future novel coronaviruses and begin investigation into broadly protective countermeasures such as vaccines to mitigate this risk.

Learning Objectives:

1. Understand the spread of SARS-CoV-2 in the first 6 months of the pandemic, the limitations of testing, and how this impacts the overall epidemiologic data being used to direct public health measures

2. Understand what we can learn from these data and how we can alter our future pandemic responses to reduce the negative consequences of a pandemic

3. Understand the need for broadly protective vaccines/countermeasures, how we failed in the past, what research needs to be done, how novel vaccines they could be evaluated, and what real expectations are for them


Show Resources
You May Also Like
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 08, 2021 11:00 AM PDT
C.E. CREDITS
APR 08, 2021 11:00 AM PDT
Date: April 8, 2021 Time: 11:00am (PDT), 3:00pm (EDT) Pneumonia is a deadly condition with clinical outcomes highly dependent on prompt and appropriate therapy. Diagnosis of pneumonia is cha...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
Loading Comments...
Show Resources
Attendees
  • See more